$1.51
+0.09 (+6.34%)
Open$1.48
Previous Close$1.42
Day High$1.55
Day Low$1.44
52W High$20.51
52W Low$7.92
Volume—
Avg Volume394.6K
Market Cap40.14M
P/E Ratio23.40
EPS$0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+1,017.2% upside
Current
$1.51
$1.51
Target
$16.87
$16.87
$11.09
$16.87 avg
$25.84
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.17M | 11.20M | 11.67M |
| Net Income | 1.39M | 1.78M | 1.44M |
| Profit Margin | 11.4% | 15.9% | 12.3% |
| EBITDA | 2.67M | 2.32M | 2.58M |
| Free Cash Flow | 1.15M | 977.1K | 708.5K |
| Rev Growth | +22.0% | +3.1% | +2.1% |
| Debt/Equity | 0.52 | 0.37 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |